VCYT vs. IBRX

Last updated Apr 1, 2026

Compare and contrast key facts about Veracyte, Inc. (VCYT) and ImmunityBio, Inc. (IBRX).

Performance

VCYT vs. IBRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Veracyte, Inc. (VCYT) and ImmunityBio, Inc. (IBRX). The values are adjusted to include any dividend payments, if applicable.

VCYT vs. IBRX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
VCYT Veracyte, Inc.	-23.49%	6.31%	43.95%	15.93%	-42.40%	-15.82%	75.29%	121.94%	92.65%	-15.63%
IBRX ImmunityBio, Inc.	287.37%	-22.66%	-49.00%	-0.99%	-16.61%	-54.39%	251.72%	226.72%	-74.16%	-21.50%

Fundamentals

Market Cap VCYT : $2.62B IBRX : $7.59B
EPS VCYT : $0.83 IBRX : -$0.37
PS Ratio VCYT : 5.00 IBRX : 63.74
Total Revenue (TTM) VCYT : $517.15M IBRX : $113.29M
Gross Profit (TTM) VCYT : $362.53M IBRX : $112.54M
EBITDA (TTM) VCYT : $74.62M IBRX : -$257.20M

Returns By Period

In the year-to-date period, VCYT achieves a -23.49% return, which is significantly lower than IBRX's 287.37% return. Over the past 10 years, VCYT has outperformed IBRX with an annualized return of 19.69%, while IBRX has yielded a comparatively lower -1.17% annualized return.

VCYT

• 1D: 5.81%
• 1M: -11.97%
• YTD: -23.49%
• 6M: -6.18%
• 1Y: 8.63%
• 3Y*: 13.04%
• 5Y*: -9.38%
• 10Y*: 19.69%

IBRX

• 1D: 15.17%
• 1M: -21.57%
• YTD: 287.37%
• 6M: 211.79%
• 1Y: 154.82%
• 3Y*: 61.53%
• 5Y*: -19.29%
• 10Y*: -1.17%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

VCYT vs. IBRX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VCYT

VCYT Risk / Return Rank: 46
VCYT Sharpe Ratio Rank: 47
VCYT Sortino Ratio Rank: 48
VCYT Omega Ratio Rank: 45
VCYT Calmar Ratio Rank: 46
VCYT Martin Ratio Rank: 46

IBRX

IBRX Risk / Return Rank: 84
IBRX Sharpe Ratio Rank: 84
IBRX Sortino Ratio Rank: 87
IBRX Omega Ratio Rank: 83
IBRX Calmar Ratio Rank: 88
IBRX Martin Ratio Rank: 79

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VCYT vs. IBRX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Veracyte, Inc. (VCYT) and ImmunityBio, Inc. (IBRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	VCYT	IBRX	Difference
Sharpe ratio Return per unit of total volatility	0.16	1.44	-1.28
Sortino ratio Return per unit of downside risk	0.72	2.54	-1.81
Omega ratio Gain probability vs. loss probability	1.08	1.31	-0.23
Calmar ratio Return relative to maximum drawdown	0.18	3.40	-3.22
Martin ratio Return relative to average drawdown	0.41	5.58	-5.17
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

VCYT vs. IBRX - Sharpe Ratio Comparison

The current VCYT Sharpe Ratio is 0.16, which is lower than the IBRX Sharpe Ratio of 1.44. The chart below compares the historical Sharpe Ratios of VCYT and IBRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	VCYT	IBRX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.16	1.44	-1.28
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.15	-0.17	+0.02
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.32	-0.01	+0.33
Sharpe Ratio (All Time) Calculated using the full available price history	0.12	-0.12	+0.24

Correlation

The correlation between VCYT and IBRX is 0.36, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

VCYT vs. IBRX - Dividend Comparison

Neither VCYT nor IBRX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

VCYT vs. IBRX - Drawdown Comparison

The maximum VCYT drawdown since its inception was -81.19%, smaller than the maximum IBRX drawdown of -97.14%. Use the drawdown chart below to compare losses from any high point for VCYT and IBRX.

Drawdown Indicators

	VCYT	IBRX	Difference
Max Drawdown Largest peak-to-trough decline	-81.19%	-97.14%	+15.95%
Max Drawdown (1Y) Largest decline over 1 year	-39.23%	-42.44%	+3.21%
Max Drawdown (5Y) Largest decline over 5 years	-72.96%	-94.40%	+21.44%
Max Drawdown (10Y) Largest decline over 10 years	-81.19%	-97.03%	+15.84%
Current Drawdown Current decline from peak	-60.42%	-81.85%	+21.43%
Average Drawdown Average peak-to-trough decline	-48.28%	-83.94%	+35.66%
Ulcer Index Depth and duration of drawdowns from previous peaks	17.00%	25.86%	-8.86%

Volatility

VCYT vs. IBRX - Volatility Comparison

The current volatility for Veracyte, Inc. (VCYT) is 16.05%, while ImmunityBio, Inc. (IBRX) has a volatility of 38.29%. This indicates that VCYT experiences smaller price fluctuations and is considered to be less risky than IBRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	VCYT	IBRX	Difference
Volatility (1M) Calculated over the trailing 1-month period	16.05%	38.29%	-22.24%
Volatility (6M) Calculated over the trailing 6-month period	40.87%	87.83%	-46.96%
Volatility (1Y) Calculated over the trailing 1-year period	55.36%	108.55%	-53.19%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	64.23%	113.60%	-49.37%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	61.38%	111.61%	-50.23%

Financials